[1]
“Efficacy of dual therapy in patients >65 years old with alanine transaminase flare during chronic hepatitis C genotype 2”, Ital J Med, vol. 9, no. 1, pp. 82–88, Mar. 2015, doi: 10.4081/itjm.2015.471.